Patents by Inventor Thomas Schenke

Thomas Schenke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent number: 7122540
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: October 17, 2006
    Assignee: Bayer HealthCare AG
    Inventors: Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Semo, Marc Nowakowski, Ulrich Niewöhner, deceased
  • 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Publication number: 20060189615
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 24, 2006
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Morpoline-bridged indazole derivatives
    Publication number: 20060128700
    Abstract: The present invention relates to novel morpholine-bridged indazole derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of disorders of the central nervous system.
    Type: Application
    Filed: September 16, 2003
    Publication date: June 15, 2006
    Inventors: Achim Feurer, Joachim Luithle, Stephan-Nicholas Wirtz, Gerhard Konig, Johannes-Peter Stasch, Frank Wunder, Dieter Lang, Elke Stahl, Thomas Schenke, Rudy Schreiber
  • 7-Alkyl and cycloalkyl-substituted imidazotriazinones
    Patent number: 6943163
    Abstract: The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: September 13, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn
  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent number: 6890922
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: May 10, 2005
    Assignee: Bayer Healthcare AG
    Inventors: Maria Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski, Ulrich Niewöhner
  • [1.2]-Oxazin-3,5-diones
    Publication number: 20050070707
    Abstract: The present invention relates to novel [1,2]-oxazine-3,5-dione derivatives of the formula (I) in which W, X, Y, Z, G, D, A and B are as defined in the disclosure, to a plurality of processes for their preparation, and to their use as microbicides, pesticides and herbicides.
    Type: Application
    Filed: November 27, 2002
    Publication date: March 31, 2005
    Inventors: Reiner Fischer, Thomas Schenke, Angelika Lubos-Erdelen
  • 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Publication number: 20050070541
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: August 20, 2004
    Publication date: March 31, 2005
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • 7-Aikyl and cycloalkyl-substituted imidazotriazinones
    Publication number: 20050049250
    Abstract: The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Application
    Filed: May 20, 2004
    Publication date: March 3, 2005
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn
  • ?-phenyl-?-keto sulfones
    Patent number: 6849744
    Abstract: The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I): in which F1, F2, G, V, W, X, Y, Z and m are each as defined in the description, to processes for their preparation and to their use in agriculture, for example as crop protection agents (fungicides, herbicides and insecticides).
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: February 1, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Reiner Fischer, Oliver Kretschik, Thomas Schenke, Ralf-Ingo Schenkel, Jürgen Wiedemann, Christoph Erdelen, Peter Lösel, Mark Wilhelm Drewes, Dieter Feucht, Wolfram Andersch
  • 7-alkyl-and cycloalkyl-substituted imidazotriazinones
    Patent number: 6838459
    Abstract: The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: January 4, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn
  • Morpholine-bridged pyrazolopyridine derivatives
    Publication number: 20040235863
    Abstract: The invention relates to novel pyrazolopyridine derivatives of formula (I), wherein R1 represents (a) or (b) and n represents 1 or 2 and R2 represents H NH2. The invention also relates to salts, isomers and hydrates thereof as stimulators for soluble guanylate cyclase and to their use as agents in the treatment of cardiovascular diseases, hypertonicity, thrombo-embolic diseases and ischemia, sexual dysfunction or inflammations and for the treatment of diseases of the central nervous system.
    Type: Application
    Filed: June 28, 2004
    Publication date: November 25, 2004
    Inventors: Achim Feurer, Dietmar Flubacher, Stefan Weigand, Johannes-Peter Stasch, Elke Stahl, Thomas Schenke, Cristina Alonso-Alija, Frank Wunder, Dieter Lang, Klaus Dembowsky, Alexander Straub, Elisabeth Perzborn
  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Publication number: 20040067945
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: February 12, 2003
    Publication date: April 8, 2004
    Inventors: Ulrich Niewohner, Maria Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Alpha-phenyl-beta-ketosulfone
    Publication number: 20040063669
    Abstract: The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I) 1
    Type: Application
    Filed: June 13, 2003
    Publication date: April 1, 2004
    Inventors: Reiner Fischer, Oliver Kretschik, Thomas Schenke, Ralf-Ingo Schenkel, Jurgen Wiedemann, Christoph Erdelen, Peter Losel, Mark Wilhelm Drewes, Dieter Feucht, Wolfram Andersch
  • &agr;-phenyl-&bgr;ketosulfone
    Patent number: 6670385
    Abstract: The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I) in which F1, F2, G, V, W, X, Y, Z and m are each as defined in the description, to processes for their preparation and to their use in agriculture, for example as crop protection agents (fungicides, herbicides and insecticides).
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: December 30, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Reiner Fischer, Oliver Kretschik, Thomas Schenke, Ralf-Ingo Schenkel, Jürgen Wiedemann, Christoph Erdelen, Peter Lösel, Mark Wilhelm Drewes, Dieter Feucht, Wolfram Andersch
  • 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors
    Patent number: 6566360
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: May 20, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • 7-alkyl- and cycloalkyl-substituted imidazotriazinones
    Patent number: 6476029
    Abstract: The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: November 5, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn
  • Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
    Patent number: 6458796
    Abstract: The present invention relates to novel dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: October 1, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Helmut Haning, Ulrich Niewöhner, Ulrich Rosentreter, Thomas Schenke, Erwin Bischoff, Karl-Heinz Schlemmer
  • USE OF 7-(2-OXA-5,8-DIAZABICYLCO[4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELIOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES
    Patent number: 6432948
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives, which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: August 13, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Michael Matzke, Uwe Petersen, Thomas Jaetsch, Stephan Bartel, Thomas Schénke, Thomas Himmler, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski
  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent number: 6362178
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: March 26, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders
    Publication number: 20010036941
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in position 7 by a 1-aninomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl radical, and of their salts for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders.
    Type: Application
    Filed: April 10, 2001
    Publication date: November 1, 2001
    Inventors: Uwe Petersen, Michael Matzke, Thomas Jaetsch, Thomas Schenke, Thomas Himmler, Stephan Bartel, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski, Rainer Endermann